0000000001079075

AUTHOR

Schoenen Jean

showing 2 related works from this author

Altered processing of sensory stimuli in patients with migraine.

2014

Migraine is a cyclic disorder, in which functional and morphological brain changes fluctuate over time, culminating periodically in an attack. In the migrainous brain, temporal processing of external stimuli and sequential recruitment of neuronal networks are often dysfunctional. These changes reflect complex CNS dysfunction patterns. Assessment of multimodal evoked potentials and nociceptive reflex responses can reveal altered patterns of the brain's electrophysiological activity, thereby aiding our understanding of the pathophysiology of migraine. In this Review, we summarize the most important findings on temporal processing of evoked and reflex responses in migraine. Considering these d…

TRANSCRANIAL MAGNETIC STIMULATIONSensory processingmedicine.medical_treatmentMigraine DisordersThalamocortical dysrhythmiaEVENT-RELATED POTENTIALSINTENSITY-DEPENDENCESensory systemElectroencephalographyCellular and Molecular Neurosciencesensory stimuli migraine neurophysiology thalamo-cortical dysrtmia.Event-related potentialNociceptive ReflexPhysical StimulationPHASE SYNCHRONIZATION CHANGESReflexMedicine and Health SciencesmedicineHumansHIGH-FREQUENCY OSCILLATIONSEvoked PotentialsMigraineNOCICEPTIVE BLINK REFLEXCONTINGENT NEGATIVE-VARIATIONMEDICATION-OVERUSE HEADACHEmedicine.diagnostic_testbusiness.industryBrainElectroencephalographyAUDITORY-EVOKED-POTENTIALSmedicine.diseaseMigraineconnectivitySensation DisordersReflexVISUAL-CORTEX EXCITABILITYNeurology (clinical)businesssynchronizationNeuroscienceNature reviews. Neurology
researchProduct

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine : a phase 2 randomised, placebo-control…

2012

Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral lasmiditan for the acute treatment of migraine.In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo. Study drug and placebo were sup…

AdultMaleDrug-Related Side Effects and Adverse ReactionsPyridinesPopulationMedizinAdministration OralKaplan-Meier EstimatePlacebolaw.inventionYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodPiperidinesRandomized controlled triallawHumansMedicineAdverse effecteducationAgededucation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle AgedDose-ranging studymedicine.diseaseLasmiditanSerotonin Receptor Agonists3. Good healthTreatment OutcomechemistryTolerabilityMigraine030220 oncology & carcinogenesisAnesthesiaBenzamidesFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct